学位論文 Sodium-glucose cotransporter 2 inhibitor and a low carbohydrate diet affect gluconeogenesis and glycogen content differently in the kidney and the liver of non-diabetic mice (Sodium-glucose cotransporter 2 ( SGLT 2 )

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Amendment history : Corrigendum ( May 2014 ) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

  2018cited by this paper
• Impact of obesity on cardiovascular disease

  2017cited by this paper
• Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis

  2016cited by this paper
• The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.

  2016cited by this paper
• Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice.

  2016cited by this paper
• Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction

  2016cited by this paper
• Atkins diet program rapidly decreases atherogenic index of plasma in trained adapted overweight men.

  2015cited by this paper
• A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans

  2015cited by this paper
• Cardiovascular Disease Mortality: The Deleterious Effects of Excess Dietary Sugar Intake

  2015cited by this paper
• Excess intake of fat and sugar potentiates epinephrine-induced hyperglycemia in male rats.

  2015cited by this paper
• The Effects of a Low-Carbohydrate Diet vs. a Low-Fat Diet on Novel Cardiovascular Risk Factors: A Randomized Controlled Trial

  2015cited by this paper
• Sugar-Induced Aging: The Deleterious Effects of Excess Dietary Sugar Intake

  2015cited by this paper
• A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus

  2015cited by this paper
• Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

  2015cited by this paper
• SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

  2014cited by this paper
• Dapagliflozin: glucuretic action and beyond.

  2014cited by this paper
• Long-Term Low Carbohydrate Diet Leads to Deleterious Metabolic Manifestations in Diabetic Mice

  2014cited by this paper
• Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

  2014cited by this paper
• Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

  2014cited by this paper
• The Influence of Dietary Fat on Liver Fat Accumulation

  2014cited by this paper
• Glycogen shortage during fasting triggers liver–brain–adipose neurocircuitry to facilitate fat utilization

  2013cited by this paper
• Regional distribution of SGLT activity in rat brain in vivo.

  2013cited by this paper
• Carbohydrate nutrition and development of adiposity during adolescence

  2013cited by this paper
• Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.

  2013cited by this paper
• Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet‐Induced Obese (DIO) Rats

  2012cited by this paper
• Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice

  2012cited by this paper
• Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

  2012cited by this paper
• Overweight and obesity as risk factors in hypertension--study of the working population.

  2011cited by this paper
• Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

  2011cited by this paper
• Functional expression of SGLTs in rat brain.

  2010cited by this paper
• Therapeutic role of low-carbohydrate ketogenic diet in diabetes.

  2009cited by this paper
• Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss.

  2009cited by this paper
• Renal carcinogenesis in models of diabetes in rats—metabolic changes are closely related to neoplastic development

  2007cited by this paper
• Sodium-Coupled Glucose Cotransporters Contribute to Hypothalamic Glucose Sensing

  2006cited by this paper
• The staining of glycogen with Best's Carmine and similar hydrogen bonding dyes. A mechanistic study

  2005cited by this paper
• Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction.

  2003cited by this paper
• CREB regulates hepatic gluconeogenesis through the coactivator PGC-1

  2001cited by this paper
• Renal gluconeogenesis: its importance in human glucose homeostasis.

  2001cited by this paper
• High-monounsaturated fat diet-induced obesity and diabetes in C57BL/6J mice.

  1998cited by this paper
• Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine.

  1995cited by this paper
• Hyperinsulinemic obesity and carbohydrate addiction: the missing link is the carbohydrate frequency factor.

  1994cited by this paper
• Fatty liver in rats induced by excessive intake of a nutritionally adequate liquid diet.

  1987cited by this paper
• Renal substrate metabolism.

  1986cited by this paper
• Renal lipid metabolism.

  1983cited by this paper
• The pathology of Armanni-Ebstein diabetic nephropathy.

  1957cited by this paper

• Diabetes duration and types of diabetes treatment in data-driven clusters of patients with diabetes

  2022cites this paper